Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.

Autor:	Mon MM; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand., Srisomsap C; Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand., Chokchaichamnankit D; Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand., Watcharatanyatip K; Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand., Weeraphan C; Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand., Svasti J; Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand., Maneechai K; Department of Biology, Faculty of Sciences, Prince of Songkla University, Songkhla, Thailand., Thongsuksai P; Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand., Raungrut P; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; rpritsan@medicine.psu.ac.th.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2021 Apr; Vol. 41 (4), pp. 1871-1882.
DOI:	10.21873/anticanres.14953
Abstrakt:	Background: This study aimed to identify differentially expressed proteins in the serum of advanced non-small cell lung cancer (NSCLC) patients responding to carboplatin (CAR) plus paclitaxel (PTX) chemotherapy compared to non-responders. Materials and Methods: Serum from 8 responders and 6 non-responders was subjected to proteomic analysis by label-free liquid chromatography tandem mass spectrometry and validated by western blotting. CAR/PTX-resistant human H1792 and A549 cells were used for evaluating gene expression. Results: Fifty-two proteins were differentially expressed between responders and non-responders. Alpha 1 antitrypsin antibody, alpha 1 acid glycoprotein (A1AG1), afamin, protein S100-A9 and immunoglobulin heavy constant gamma 3 (IGHG3) were validated. IGHG3 was elevated (p=0.037) while A1AG1 was reduced (p=0.003) in responders as compared to non-responders. Gene expression of IGHG3 and ORM1 in resistant cells showed consistent results with the proteomics profiles. Conclusion: Serum expression levels of IGHG3 and A1AG1 proteins may be useful to recruit an NSCLC subpopulation that can benefit from CAR plus PTX standard therapy. (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu